Benitez Jose Carlos, Remon Jordi, Besse Benjamin
Gustave Roussy, Department of Cancer Medicine, Villejuif, France.
Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
Clin Cancer Res. 2020 Oct 1;26(19):5068-5077. doi: 10.1158/1078-0432.CCR-19-3255. Epub 2020 May 20.
Immune checkpoint inhibitors (ICI) may overcome cancer cells' ability to evade the immune system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate neoadjuvant ICI approaches in several tumor types such as melanoma, non-small cell lung cancer, and breast and bladder cancer. We summarize the current evidence for the efficacy of neoadjuvant ICI in cancer and discuss several unresolved challenges, including the role of adjuvant treatment after neoadjuvant ICI, the efficacy in oncogenic addicted tumors, and standardizing pathologic assessment.
免疫检查点抑制剂（ICI）可能会克服癌细胞逃避免疫系统并增殖的能力。ICI在转移性疾病中的长期益处促使人们评估其在多种肿瘤类型（如黑色素瘤、非小细胞肺癌、乳腺癌和膀胱癌）中的新辅助治疗方法。我们总结了目前关于新辅助ICI治疗癌症疗效的证据，并讨论了几个尚未解决的挑战，包括新辅助ICI治疗后辅助治疗的作用、对致癌成瘾肿瘤的疗效以及病理评估的标准化。
